Next Article in Journal
Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity
Next Article in Special Issue
Blocking Plasmodium falciparum Malaria Transmission with Drugs: The Gametocytocidal and Sporontocidal Properties of Current and Prospective Antimalarials
Previous Article in Journal
Effects of Moxifloxacin on Human Neutrophil and T-Lymphocyte Functions in Vitro
Previous Article in Special Issue
Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria
Pharmaceuticals 2010, 3(12), 3581-3593; doi:10.3390/ph3123581
Review

Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress

1,*  and 2
1 Centre for Health Research, Divine Word University, P O Box 483, Madang 555, Madang Province, Papua New Guinea 2 Medical Research Institute, Kunming Pharma, West suburb, Xishan Region, Kunming, China
* Author to whom correspondence should be addressed.
Received: 15 November 2010 / Revised: 8 December 2010 / Accepted: 9 December 2010 / Published: 14 December 2010
(This article belongs to the Special Issue New Antimalarial Drugs)
View Full-Text   |   Download PDF [205 KB, uploaded 14 December 2010]   |   Browse Figures

Abstract

With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria.
Keywords: artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum artemisinin-naphthoquine combination; ARCO; artemisinin; naphthoquine; Plasmodium falciparum
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Hombhanje, F.W.; Huang, Q. Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress. Pharmaceuticals 2010, 3, 3581-3593.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert